These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22402319)

  • 21. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.
    Morris JC; Ramlogan-Steel CA; Yu P; Black BA; Mannan P; Allison JP; Waldmann TA; Steel JC
    Gene Ther; 2014 Apr; 21(4):393-401. PubMed ID: 24572789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.
    Laborda E; Puig-Saus C; Rodriguez-García A; Moreno R; Cascalló M; Pastor J; Alemany R
    Mol Ther; 2014 May; 22(5):986-98. PubMed ID: 24448161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.
    Vigna E; Pacchiana G; Chiriaco C; Cignetto S; Fontani L; Michieli P; Comoglio PM
    J Mol Med (Berl); 2014 Jan; 92(1):65-76. PubMed ID: 24013625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).
    Azab BM; Dash R; Das SK; Bhutia SK; Sarkar S; Shen XN; Quinn BA; Dent P; Dmitriev IP; Wang XY; Curiel DT; Pellecchia M; Reed JC; Sarkar D; Fisher PB
    J Cell Physiol; 2014 Jan; 229(1):34-43. PubMed ID: 23868767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.
    Freytag SO; Barton KN; Zhang Y
    Gene Ther; 2013 Dec; 20(12):1131-9. PubMed ID: 23842593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral mediated expression of a NGF-soluble Nogo receptor 1 fusion protein promotes axonal regeneration.
    Zhang Y; Gao F; Wu D; Moshayedi P; Zhang X; Ellamushi H; Yeh J; Priestley JV; Bo X
    Neurobiol Dis; 2013 Oct; 58():270-80. PubMed ID: 23811498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.
    Johnson TJ; Höti N; Liu C; Chowdhury WH; Li Y; Zhang Y; Lupold SE; Deweese T; Rodriguez R
    Cancer Gene Ther; 2013 Jul; 20(7):394-402. PubMed ID: 23764901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
    Cheema TA; Wakimoto H; Fecci PE; Ning J; Kuroda T; Jeyaretna DS; Martuza RL; Rabkin SD
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12006-11. PubMed ID: 23754388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.
    Hsu C; Abad JD; Morgan RA
    J Surg Res; 2013 Sep; 184(1):282-9. PubMed ID: 23582229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
    Heldermon CD; Qin EY; Ohlemiller KK; Herzog ED; Brown JR; Vogler C; Hou W; Orrock JL; Crawford BE; Sands MS
    Gene Ther; 2013 Sep; 20(9):913-21. PubMed ID: 23535899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.
    Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG
    Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.
    Yokoyama H; Oguchi T; Goins WF; Goss JR; Nishizawa O; de Groat WC; Wolfe D; Krisky DM; Glorioso JC; Yoshimura N
    Hum Gene Ther; 2013 Feb; 24(2):170-80. PubMed ID: 23316929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
    Muthana M; Rodrigues S; Chen YY; Welford A; Hughes R; Tazzyman S; Essand M; Morrow F; Lewis CE
    Cancer Res; 2013 Jan; 73(2):490-5. PubMed ID: 23172310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.
    Yuan Z; Syrkin G; Adem A; Geha R; Pastoriza J; Vrikshajanani C; Smith T; Quinn TJ; Alemu G; Cho H; Barrett CJ; Arap W; Pasqualini R; Libutti SK
    Cancer Gene Ther; 2013 Jan; 20(1):46-56. PubMed ID: 23154431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
    Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
    Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.
    Miura Y; Yamasaki S; Davydova J; Brown E; Aoki K; Vickers S; Yamamoto M
    Mol Ther; 2013 Jan; 21(1):139-48. PubMed ID: 23032977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
    Cobo M; Anderson P; Benabdellah K; Toscano MG; Muñoz P; García-Pérez A; Gutierrez I; Delgado M; Martin F
    Cell Transplant; 2013; 22(5):839-54. PubMed ID: 23031550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy.
    Trujillo MA; Oneal MJ; McDonough SJ; Morris JC
    Gene Ther; 2013 May; 20(5):567-74. PubMed ID: 22972493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lentiviral-mediated administration of IL-25 in the CNS induces alternative activation of microglia.
    Maiorino C; Khorooshi R; Ruffini F; Løbner M; Bergami A; Garzetti L; Martino G; Owens T; Furlan R
    Gene Ther; 2013 May; 20(5):487-96. PubMed ID: 22855093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.